The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

With the acquisition, Boehringer Ingelheim strengthens its animal health ... and increased pet owner convenience and compliance. “Our pets live longer which creates different needs for their ...

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...

(Bloomberg) -- Drugmakers GSK Plc and Boehringer Ingelheim GmbH persuaded a Chicago ... Paris-based Sanofi — Zantac’s current ...

1,5 Full efficacy and safety data from the trial will be presented in the first half of 2025. Boehringer Ingelheim will submit a new drug application for nerandomilast for the treatment of IPF to the ...

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D ...

With the acquisition, Boehringer Ingelheim strengthens its animal health research and ... better treatment outcomes, and increased pet owner convenience and compliance. “Our pets live longer which ...